1st Annual Canadian Biomarker and Surrogate Endpoints Symposium

January 5, 2009 - Ottawa, Ontario

Opening Remarks -  Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School; Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal

Quantitative Coronary Arteriography to Assess the Effect of Pharmacologic Agents on the Progression/Regression of Coronary Atherosclerosis - David Waters, MD, University of California, San Francisco

Intravascular Ultrasound - Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal

Carotid Intima Media Thickness: Use in Cardiovascular Risk Assessment and in Clinical Trials - Eva Lonn, MD, McMaster University

Carotid Ultrasound Phenotypes: Assessing Atherosclerosis Burden and Response to Therapy - J. David Spence, MD, Robarts Research Institute

Magnetic Resonance Imaging - Alan Moody, MD Sunnybrook Health Sciences Centre

Computed Tomography and Positron Emission Tomography - Zahi Fayad, MD, Mount Sinai School of Medicine

PET as a Tool For Molecular Imaging - Robert Beanlands, MD, University of Ottawa Heart

Panel Discussion - Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School;  Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal;  David Waters, MD, University of California, San Francisco;  J. David Spence, Robarts Research Institute;  Alan Moody, MD Sunnybrook Health Sciences Centre;  Zahi Fayad, MD, Mount Sinai School of Medicine;  Robert Beanlands, MD, University of Ottawa Heart; Eva Lonn, MD, McMaster University

New Development in Atherosclerosis Imaging Technologies - Philippe L’Allier, MD, Montreal Heart Institute

Cardiovascular Imaging Initiatives - Peter Liu, MD, Canadian Institutes of Health Research

Rewards and Risks of using Surrogate Endpoints in the Approval of Drugs - Agnes Klein, MD, Health Canad 

Panel Discussion - Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School; Jean-Claude Tardif, MD, Montreal Heart Institute, University of Montreal; Philippe L’Allier, MD, Montreal Heart Institute; Peter Liu, MD, Canadian Institutes of Health Research; Agnes Klein, MD, Health Canada

Molecular Imaging Innovations in Cardiovascular Disease - Peter Libby, MD, Brigham and Women’s Hospital, Harvard Medical School

An Approach to the Commercial Development of Molecular Imaging Agents - Allison Mueller, Director, GE Healthcare

Panel Discussions: Academia, Industry and Regulatory Agency: Working Together For the Future - Faculty Member